Cost Minimization Analysis

Cost minimization analysis (CMA) is a form of economic evaluation used when two or more interventions have been demonstrated to produce equivalent health outcomes, so that the evaluation reduces to a simple comparison of costs to identify the least expensive option. Because the effectiveness dimension is held constant by the assumption of outcome equivalence, CMA does not produce an incremental cost effectiveness ratio; instead, it reports only the cost difference between alternatives. CMA is the simplest form of full economic evaluation but is appropriate only under narrow conditions that must be carefully justified.

CMA provides a clear framework for decision making when the question is not "which intervention works better?" but rather "which equally effective intervention costs less?" This situation can arise in several settings: generic drugs approved on the basis of bioequivalence, biosimilars that demonstrate clinical equivalence in trials, surgical techniques that produce the same operative outcomes, and service delivery models shown to achieve equivalent health outcomes can all be evaluated using CMA. In a resource constrained health care environment, identifying the least costly route to the same outcome is a direct path to efficiency gains.

The starting point for CMA is evidence that the alternatives produce equivalent outcomes. This evidence typically comes from equivalence or noninferiority trials, or meta analyses, showing that any difference in the primary efficacy endpoint lies within a prespecified margin. Once equivalence is established, researchers estimate the total costs of each alternative from a specified perspective (health system, societal, or patient). Cost categories include direct medical costs (drug acquisition, administration, monitoring, management of adverse events), direct nonmedical costs, and sometimes indirect costs. The alternative with the lowest total cost is identified as the preferred option. Sensitivity analyses test how the cost comparison changes when unit costs, resource use patterns, or time horizons are varied.

Use CMA only when there is strong evidence that the interventions being compared produce clinically equivalent outcomes. Appropriate contexts include evaluating generic versus branded pharmaceuticals, comparing biosimilars to reference biologics after equivalence trials, and assessing alternative delivery modes for the same treatment. CMA is not appropriate when there is real uncertainty about whether outcomes differ, because a small difference in effectiveness could change the conclusions entirely. If outcome equivalence is uncertain, cost effectiveness analysis or cost utility analysis is the more appropriate method.

The most consequential mistake is assuming outcome equivalence without sufficient evidence. A single small trial showing no statistically significant difference between interventions does not prove equivalence; it may simply lack the power to detect a difference. Formal equivalence or noninferiority testing, with prespecified margins and adequate sample sizes, is required. Another error is limiting the cost comparison to acquisition cost alone without considering the full cost profile; a cheaper drug that requires more frequent monitoring or has higher adverse event rates may not be less costly overall. Researchers sometimes fail to specify the perspective of the analysis, which determines which costs are relevant. Finally, omitting sensitivity analysis leaves the conclusion untested against plausible variations in key parameters.

A hospital pharmacy evaluates whether to switch from a branded proton pump inhibitor to its generic equivalent. Bioequivalence studies have shown that the generic delivers the same drug exposure as the branded product, which is the basis for expecting equivalent acid suppression and symptom relief. The pharmacist conducts a CMA from the hospital perspective, calculating total costs per patient over six months, including acquisition cost, dispensing cost, and management of any adverse events. The generic alternative costs $340 per patient compared with $890 for the branded product, a saving of $550 per patient. Sensitivity analysis confirms that the generic remains less costly even when all its costs are assumed to be 20% higher ($408 per patient, still well below $890). The formulary committee approves the switch.